CNR1 and obesity disorder: To date, endocannabinoids act as orexigenic factors, stimulating food intake and fat deposition [97]; consistently, rimonabant (SR141716, Acomplia), the selective CB1 antagonist used in clinical trials for the treatment of obesity, reduces body weight, but due to severe psychiatric side effects, its use in patients has been discontinued [98].